In­cyte scores speedy FDA re­view for JAK cream in atopic der­mati­tis; Lil­ly backs $90M raise for Re­gor

In­cyte’s stal­wart JAK in­hibitor Jakafi has raced out to block­buster sales with­out the safe­ty bur­den of oth­er drugs in the class. Now, the drug­mak­er’s quest …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.